DEL PHARMA financials
A multi-period view of the public annual-account figures reported for DEL PHARMA, with comparable measures and links to available source documents.
Company overviewRegistry number
0721527966
Fiscal coverage
2024–2025
Public sources
cbso_bulk
Data updated
Jul 29, 2026
Financial evidence
Latest movements for DEL PHARMA
2025 versus 2024
- Operating line
- €19,174
- EBITDA
- €18,511
- Total assets
- €36,943
- Equity
- €16,307
+37.9%
+38.7%
+10.9%
+57.7%
EBITDA margin +96.5% · Equity ratio +44.1%
Multi-year filings
Source: NBB/CBSOFiled annual accounts by fiscal year
Public regulator-filed figures across 2 years.
Fiscal year | Gross margin | EBITDA | Total assets | Equity | Filing |
|---|---|---|---|---|---|
| 202531 Dec 2025 | €19,174 | €18,511 | €36,943 | €16,307 | - |
| 202431 Dec 2024 | €13,908 | €13,344 | €33,315 | €10,340 | - |
Figures reproduce public filings and may use country-specific accounting definitions. They are not audited by Upswitch.